Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
UCLH CANCER ACADEMY
UCLH CANCER ACADEMY The Cancer Academy was launched in late 2016 as a key part of the UCLH Cancer Strategy. The Academy responds to the need for improving patient experience and provides programmes for people affected by cancer. It also responds to an opportunity to support staff in realising their full potential. The Cancer Academy works closely with The University College Hospital (UCH)… View more
Cardiac Toxicity of Cancer Chemotherapy
Author(s): Aarti Asnani Start date: Aug 08, 2017

Heart Failure
Author(s): Alessandra Cuomo , Alessio Rodolico , Amalia Galdieri , et al Added: 3 years ago
The increasing progress in cancer therapies has reduced mortality rates for many cancers. Unfortunately, many life-saving therapies are burdened by the risk of cardiotoxicity (CTX). The cardiovascular system appears to be particularly susceptible to the action of many anti-neoplastic drugs, which may cause vasospastic or thromboembolic ischaemia, arterial hypertension, dysrhythmia, and left… View more

Heart Failure

CV Disease in Special Populations
Author(s): Carine E Hamo , Michelle W Bloom Added: 3 years ago
Heart disease and cancer are the two leading causes of death, together accounting for almost 50 % of deaths in the US.1 Unfortunately, the tremendous success in improving cancer survival is often attenuated by downstream cardiovascular complications from cancer therapy. Acute cardiac toxicity may limit the ability to use life-saving cancer therapy and chronic toxicity limits overall survival. As… View more

Heart Failure

CV Disease in Special Populations
Author(s): Mark Sweeney , Angela Yiu , Alexander Lyon Added: 3 years ago
Cancer and the anti-cancer treatments prescribed by oncologists have long been known to have significant effects on muscle, causing a catabolic muscle wasting state and resulting in widespread and progressive atrophy of most muscle groups.1 This process contributes significantly to the cancer cachexia seen in up to 80% of all patients with cancer, resulting in progressive weight loss, loss of… View more

Heart Failure
Cardio-oncology Discussion: Primary PCI in Cancer Patients
Author(s): Arjun K Ghosh , Deepak L Bhatt , Cezar Iliescu Added: 2 years ago
Cardio-oncology topic editor, Dr Arjun Ghosh (University College London Hospital and Hatter Cardiovascular Institute, UK) is joined by Dr. Deepak L. Bhatt (Brigham and Women's Hospital, Medical School, US) and Dr Cezar Iliescu(The University of Texas MD Anderson Cancer Center, US) to discuss interventional issues in cancer patients with a focus on patients with acute coronary syndromes (ACS)… View more

Intervention

CV Disease in Special Populations
ACC 23: Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial
Author(s): Marielle Scherrer-Crosbie Added: 1 year ago
ACC.23/WCC — In this succinct late-breaking science interview, Investigator, Dr Marielle Scherrer-Crosbie (Hospital of the University of Pennsylvania, US) discusses the results from the STOP-CA trial (Massachusetts General Hospital). This randomized phase II trial aims to investigate whether atorvastatin, a commonly prescribed statin drug for reducing cholesterol levels, can protect the heart… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Edoardo Bertero , Pietro Ameri , Christoph Maack Added: 3 years ago
Heart failure (HF) and cancer represent two major causes of morbidity and mortality in developed countries.1,2 The prevalence of these conditions is growing as the age of the population and the burden of shared risk factors, such as diabetes and obesity, are constantly increasing. In past decades, the field of cardio-oncology has predominantly focused on prevention and treatment of cardiovascular… View more

Heart Failure

CV Disease in Special Populations
Randall A. Oyer
Research Area(s) / Expertise:

Cardio-oncology

 Job title: Medical Director, Ann B. Barhshinger Cancer Institute, Lancaster General Hospital, University of Pennsylvania, US
Medical oncologist Randall A. Oyer, MD, practices at Penn Medicine Lancaster General's Ann B. Barshinger Cancer Institute in Lancaster, Pennsylvania. At Penn Medicine Lancaster General, Dr. Oyer holds the positions of medical director of the cancer institute, director of oncology, chairman of the cancer committee, chair of the oncology physicians advisory council, and medical director of the… View more
Research Area(s) / Expertise:

Cardio-oncology

 Job title: Department of Nursing, Division of SrVP and Chief Nursing Officer
Dr. Anecita P. Fadol earned her nursing diploma from the CLMMH School of Nursing and a Bachelor of Science in Nursing from Riverside College, Bacolod City, Philippines. Her academic journey continued with honors as she completed a Master of Science in Nursing specializing in Critical Care Nursing from the University Of Texas Health Science Center, Houston, Texas. Dr. Fadol further enriched her… View more